151 related articles for article (PubMed ID: 38562164)
41. The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations.
Hernandez L; Young M
J Manag Care Spec Pharm; 2023 Feb; 29(2):172-186. PubMed ID: 36373869
[No Abstract] [Full Text] [Related]
42. Technology versus tradition: a non-inferiority trial comparing video to face-to-face consultations with a physiotherapist for people with knee osteoarthritis. Protocol for the PEAK randomised controlled trial.
Hinman RS; Kimp AJ; Campbell PK; Russell T; Foster NE; Kasza J; Harris A; Bennell KL
BMC Musculoskelet Disord; 2020 Aug; 21(1):522. PubMed ID: 32767989
[TBL] [Abstract][Full Text] [Related]
43. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.
Patterson BJ; Herring WL; Van Oorschot D; Curran D; Carrico J; Zhang Y; Ackerson BK; Bruxvoort K; Sy LS; Tseng HF
J Manag Care Spec Pharm; 2020 Dec; 26(12):1567-1575. PubMed ID: 33043821
[TBL] [Abstract][Full Text] [Related]
44. Budget impact analysis of ixabepilone used according to FDA approved labeling in treatment-resistant metastatic breast cancer.
Ho J; Zhang L; Todorova L; Whillans F; Corey-Lisle P; Yuan Y
J Manag Care Pharm; 2009; 15(6):467-75. PubMed ID: 19610679
[TBL] [Abstract][Full Text] [Related]
45. Does Screening for Depressive Symptoms Help Optimize Duloxetine Use in Knee Osteoarthritis Patients With Moderate Pain? A Cost-Effectiveness Analysis.
Lenhard NK; Sullivan JK; Ross EL; Song S; Edwards RR; Hunter DJ; Neogi T; Katz JN; Losina E
Arthritis Care Res (Hoboken); 2022 May; 74(5):776-789. PubMed ID: 33253496
[TBL] [Abstract][Full Text] [Related]
46. Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan.
Proudman D; Miller A; Nellesen D; Gomes A; Mankoski R; Norregaard C; Sullivan E
JAMA Netw Open; 2020 Nov; 3(11):e2025866. PubMed ID: 33201235
[TBL] [Abstract][Full Text] [Related]
47. Affordability and Value in Decision Rules for Cost-Effectiveness: A Survey of Health Economists.
Bilinski A; MacKay E; Salomon JA; Pandya A
Value Health; 2022 Jul; 25(7):1141-1147. PubMed ID: 35219599
[TBL] [Abstract][Full Text] [Related]
48. Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a U.S. Commercial Payer Perspective.
Stellato D; Gerbasi ME; Ndife B; Ghate SR; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
J Manag Care Spec Pharm; 2019 Nov; 25(11):1227-1237. PubMed ID: 31663466
[TBL] [Abstract][Full Text] [Related]
49. Cost-effectiveness of generic celecoxib in knee osteoarthritis for average-risk patients: a model-based evaluation.
Losina E; Usiskin IM; Smith SR; Sullivan JK; Smith KC; Hunter DJ; Messier SP; Paltiel AD; Katz JN
Osteoarthritis Cartilage; 2018 May; 26(5):641-650. PubMed ID: 29481917
[TBL] [Abstract][Full Text] [Related]
50. US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma.
Bassali J; Gould IG; Kaye JA; Mladsi D; Mehta J
Clinicoecon Outcomes Res; 2020; 12():317-325. PubMed ID: 32606848
[TBL] [Abstract][Full Text] [Related]
51. Stance-Control Knee-Ankle-Foot Orthoses for People With Knee Instability: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(11):1-96. PubMed ID: 34484485
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness of an 8-week supervised education and exercise therapy programme for knee and hip osteoarthritis: a pre-post analysis of 16 255 patients participating in Good Life with osteoArthritis in Denmark (GLA:D).
Grønne DT; Roos EM; Ibsen R; Kjellberg J; Skou ST
BMJ Open; 2021 Dec; 11(12):e049541. PubMed ID: 34903537
[TBL] [Abstract][Full Text] [Related]
53. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
[TBL] [Abstract][Full Text] [Related]
54. Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration.
Losina E; Michl G; Collins JE; Hunter DJ; Jordan JM; Yelin E; Paltiel AD; Katz JN
Osteoarthritis Cartilage; 2016 May; 24(5):776-85. PubMed ID: 26746146
[TBL] [Abstract][Full Text] [Related]
55. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
Chiao E; Meyer K
Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
[TBL] [Abstract][Full Text] [Related]
56. Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Bui CN; O'Day K; Flanders S; Oestreicher N; Francis P; Posta L; Popelar B; Tang H; Balk M
J Manag Care Spec Pharm; 2016 Feb; 22(2):163-70. PubMed ID: 27015255
[TBL] [Abstract][Full Text] [Related]
57. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
Wu L; Zhong L
J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378
[TBL] [Abstract][Full Text] [Related]
58. Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain.
Merchant S; Noe LL; Howe A; Duff S; Gricar J; Ogden K; Mody SH
Clin Ther; 2013 May; 35(5):659-72. PubMed ID: 23587608
[TBL] [Abstract][Full Text] [Related]
59. Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.
Shah A; Tosh JC; Ambavane A; Nikolaou A; Hogea C; Samyshkin Y; Gorsh B; Maiese EM; Wang F
Clinicoecon Outcomes Res; 2021; 13():789-800. PubMed ID: 34531667
[TBL] [Abstract][Full Text] [Related]
60. Economic and utilization outcomes of medication management at a large Medicaid plan with disease management pharmacists using a novel artificial intelligence platform from 2018 to 2019: a retrospective observational study using regression methods.
Kessler S; Desai M; McConnell W; Jai EM; Mebine P; Nguyen J; Kiroyan C; Ho D; Von Schweber E; Von Schweber L
J Manag Care Spec Pharm; 2021 Sep; 27(9):1186-1196. PubMed ID: 34032130
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
